{"product_id":"acg-meeting-bonus-sessions-2021","title":"ACG Meeting Bonus Sessions 2021","description":"\u003cdiv class=\"titleBar\"\u003e\n\u003cdiv id=\"MainContent_MainContent_ucLearningActivityCatalog_Details___learningActivityCatalog_SideBySideDetails_pnlLearningActivitySubtitle\"\u003e\n\u003cdiv class=\"tab-panels\"\u003e\n\u003cdiv class=\"panel entry-content active\" id=\"tab-description\"\u003e\n\u003cdiv class=\"woocommerce-tabs wc-tabs-wrapper container tabbed-content\"\u003e\n\u003cdiv class=\"tab-panels\"\u003e\n\u003cdiv aria-labelledby=\"tab-title-description\" class=\"woocommerce-Tabs-panel woocommerce-Tabs-panel--description panel entry-content active\" id=\"tab-description\" role=\"tabpanel\"\u003e\n\u003cdiv class=\"so-panel widget widget_text\" data-index=\"3\" id=\"panel-817-1-0-1\"\u003e\n\u003cdiv class=\"textwidget\"\u003e\n\u003ctable class=\"table table-schedule\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cb class=\"h3 text-uppercase\"\u003eBonus Sessions\u003c\/b\u003e\u003cb\u003e\u003cem\u003eSeparate Purchase Required – Must be registered for the Annual Scientific Meeting to purchase access to these sessions.\u003c\/em\u003e\u003c\/b\u003e\n\u003cbr\u003e\u003cp class=\"text-sm\"\u003e\u003cem\u003e(Formerly Breakfast Sessions)\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003cbr\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eBonus Session A: Addressing Health Disparities in Various GI Conditions\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eModerator: Folasade P. May, MD, PhD, MPhil\u003c\/em\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eGI Cancer Disparities: Challenges and Solutions\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eFolasade P. May, MD, PhD, MPhil\u003c\/em\u003e\u003cbr\u003eDescribe the impact of disparities in GI cancers and identify approaches to increase screening rates and access to care in populations most at-risk.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLiver Transplant Continuum Among Marginalized Minorities: Identifying and Overcoming Obstacles\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eJulius M. Wilder, MD, PhD\u003c\/em\u003e\u003cbr\u003eRecognize the barriers to liver transplantation that marginalized populations often encounter and define strategies to achieve equity in transplantation.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIBD Disparities in Minority Communities: Bridging the Gap\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eAdjoa N. Anyane-Teboa, MD, MPH\u003c\/em\u003e\u003cbr\u003eIdentify racial and socioeconomic status inequities to accessing and utilizing IBD-related care.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eBonus Session B: Let’s Play Video: Recognizing Endoscopic Features of IBD\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eModerator: Anita Afzali, MD, MPH, FACG\u003c\/em\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eThe Trailer: Endoscopic Activity — Describe What You See\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eAnita Afzali, MD, MPH, FACG\u003c\/em\u003e\u003cbr\u003eAssess various levels of endoscopic activity and commonly used endoscopic scores in IBD.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eThe Watchful Eye: Colorectal Cancer and Dysplasia Surveillance\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eDavid T. Rubin, MD, FACG\u003c\/em\u003e\u003cbr\u003eDescribe endoscopic dysplastic surveillance in IBD and identify visible, discreet, and resectable lesions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAfter the Final Cut: Endoscopic Post-Surgical Anatomy in Crohn’s Disease\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eMiguel D. Regueiro, MD, FACG\u003c\/em\u003e\u003cbr\u003eDifferentiate various forms of post-surgical anatomy and recognize surgical complications during endoscopy.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eBonus Session C: Getting to the Skinny on NAFLD \u0026amp; NASH\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eModerator: Manal F. Abdelmalek, MD, MPH, FACG\u003c\/em\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eEvaluation of NAFLD\/NASH Initial Work-Up and Current Treatment Options\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eManal F. Abdelmalek, MD, MPH, FACG\u003c\/em\u003e\u003cbr\u003eDescribe an evidence-based approach to the initial work-up for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis, along with current treatment options, including lifestyle modifications and weight loss.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFuture Medical Treatments for NAFLD\/NASH\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eNaim Alkhouri, MD\u003c\/em\u003e\u003cbr\u003eSummarize evolving and future strategies for NASH treatment, including clinical trial data and implications for clinical practice.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBariatric Endoscopic and Surgical Approaches to Weight Loss for Fatty Liver Disease: What to Use When\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003ePichamol Jirapinyo, MD, MPH, and Julie K. Heimbach, MD, FACS\u003c\/em\u003e\u003cbr\u003eDiscuss and compare the role of current and evolving techniques for bariatric endoscopy vs. bariatric surgery, and their potential role in the management of non-alcoholic fatty liver disease.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eBonus Session D: Opening Up the Pipes Throughout the GI Tract\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eModerator: Jason B. Samarasena, MD, FACG\u003c\/em\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eThe Cutting Edge of Esophageal Strictures\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eJason B. Samarasena, MD, FACG\u003c\/em\u003e\u003cbr\u003eDiscuss esophageal stricture types (benign, malignant, refractory) as well as the optimal endoscopic approach for each (dilation, incisional therapy, stent, newer techniques).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMalignant Gastric Outlet Obstruction: Duodenal Stent, LAMS, or Surgery?\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eRichard A. Kozarek, MD, FACG\u003c\/em\u003e\u003cbr\u003eCompare outcomes for managing GOO with duodenal stent, EUS-guided gastroenterostomy with LAMS, and surgery; and discuss selection of optimal approach and endoscopic techniques.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFrom Volvulus to Colonic Strictures: Endoscopy Versus Surgery\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eRebecca A. Burbridge, MD\u003c\/em\u003e\u003cbr\u003eOutline best approaches for treating colonic volvulus and benign and malignant colonic strictures, including dilation and stent versus surgery.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eBonus Session E: Poopourri: Common Diarrheal Conditions of the Small Bowel\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eModerator: Baharak Moshiree, MD, MSc\u003c\/em\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eSmall Intestinal Bacterial Overgrowth: What’s New?\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eBaharak Moshiree, MD, MSc\u003c\/em\u003e\u003cbr\u003eDescribe the most up-to-date diagnostic and treatment approaches for SIBO.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eExocrine Pancreatic Insufficiency: Optimizing Your Practice\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eJodie A. Barkin, MD\u003c\/em\u003e\u003cbr\u003eRecognize symptoms of and treatment approaches for exocrine pancreatic insufficiency and identify consequences if left untreated.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eWhat’s on the Horizon for Celiac Disease and Non-Celiac Gluten Sensitivity: Serologies, Dietary, and Non-Dietary Therapies\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eBenjamin Lebwohl, MD, MS\u003c\/em\u003e\u003cbr\u003eExplore new developments in serologic testing, dietary modification, and pharmacologic therapies for celiac disease and non-celiac gluten sensitivity.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eBonus Session F: Eosinophilic Esophagitis: Present and Future\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eModerator: Amiko M. Uchida, MD\u003c\/em\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eEoE Diagnosis and Management in Adult vs Pediatric Populations\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eAmiko M. Uchida, MD, and Jacob Robson, MD\u003c\/em\u003e\u003cbr\u003eDiscuss special considerations needed for evaluating and treating EoE in children compared to adults.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eEoE Treatment: Predicting Success or Failure\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eJoy W. Chang, MD\u003c\/em\u003e\u003cbr\u003eRecognize how specific endoscopic or clinical characteristics predict treatment responses and failures in patients with EoE.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFuture of EoE: Do We Know What We Don’t Know?\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eIkuo Hirano, MD, FACG\u003c\/em\u003e\u003cbr\u003eReview controversial aspects to treatment and describe how physician-patient shared decision making can aid in management of difficult patients with EoE.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eBonus Session G: Liver Potpourri\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eModerator: Joseph K. Lim, MD FACG\u003c\/em\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eLiver Diseases and Pregnancy\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eNancy S. Reau, MD, FACG\u003c\/em\u003e\u003cbr\u003eDiscuss the management of chronic liver diseases in the context of pregnancy, and review evidence-based guidance in the evaluation and treatment of the pregnant patient with intrahepatic cholestasis, acute fatty liver, and HELLP syndrome.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFibrosure, Fibroscan, and Beyond: Using Non-Invasive Liver Fibrosis Tests in Clinical Practice\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eJoseph K. Lim, MD, FACG\u003c\/em\u003e\u003cbr\u003eReview current guidelines on non-invasive liver fibrosis tests, such as serum fibrosis assays and imaging-based elastography, in clinical practice for patients with viral hepatitis and other chronic liver disorders.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eThe Epidemic of Alcoholic Hepatitis: STOPAH the Steroids or Not? Transplant or Not?\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eAshwani K. Singal, MD, MS, FACG\u003c\/em\u003e\u003cbr\u003eSummarize new guideline recommendations in the evaluation, diagnosis, and management of severe acute alcoholic hepatitis, including the role of corticosteroids and liver transplantation.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eBonus Session H: Cutting the Fat: Bariatrics for the Gastroenterologist\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eModerator: Pichamol Jirapinyo, MD, MPH\u003c\/em\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMedical Management of Obesity\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eShelby A. Sullivan, MD, FACG\u003c\/em\u003e\u003cbr\u003eDiscuss different options for medical management of obesity including diet, exercise, and medications.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePrimary Endoscopic Bariatric and Metabolic Therapies\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eChristopher C. Thompson, MD, MSc, FACG\u003c\/em\u003e\u003cbr\u003eDescribe when to offer primary endoscopic treatment for obesity and explore current endoscopic options along with their safety and efficacy outcomes.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eEndoscopic Treatment of Weight Regain Following Bariatric Surgery\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003ePichamol Jirapinyo, MD, MPH\u003c\/em\u003e\u003cbr\u003eOutline the endoscopic approach to treating weight regain following Roux-en-Y gastric bypass and sleeve gastrectomy.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eBonus Session I: Viral Infections and the Liver\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eModerator: Stanley M. Cohen, MD, FACG\u003c\/em\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eEmerging Concepts in the Evaluation and Management of Hepatitis A and E\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eMitchell L. Shiffman, MD, FACG\u003c\/em\u003e\u003cbr\u003eSummarize the changing epidemiology, natural history, diagnosis, and management of acute hepatitis A and E infections.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHepatitis B Management: Challenges and Controversies\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eStanley M. Cohen, MD, FACG\u003c\/em\u003e\u003cbr\u003eDiscuss evidence-based approaches to challenging issues in hepatitis B management including the care of chronic HBV in pregnancy, and the evaluation, prevention, and management of HBV reactivation in patients undergoing immunosuppressive drug therapy.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHepatitis C Treatment Issues: Elimination, DAA Failures, Special Populations, Reactivation\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eKimberly A. Brown, MD\u003c\/em\u003e\u003cbr\u003eReview evidence-based guidelines addressing current challenges and controversies in HCV therapy, including HCV elimination, treatment of DAA failures and special populations, and the association between DAAs and both HCC and HBV reactivation.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eBonus Session J: Anorectal Disorders\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eModerator: Waqar A. Qureshi, MD, FACG\u003c\/em\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMotility Disorders of the Anorectum\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eLavanya Viswanathan MD, MS\u003c\/em\u003e\u003cbr\u003eIdentify when to order, how to interpret, and how to optimize treatments of various anorectal disorders using anorectal manometry.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOffice Management of Hemorrhoids and Fissures\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eWaqar A. Qureshi, MD, FACG\u003c\/em\u003e\u003cbr\u003eExplain the technique of a well-performed rectal exam, as well as medical and non-medical treatments for hemorrhoids and anal fissures, and the complications of anal fissures and hemorrhoid-based disease.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePruritus and Proctalgia Management\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eSatish S. C. Rao, MD, PhD, FACG\u003c\/em\u003e\u003cbr\u003eDescribe the pathophysiology of and differences between pruritis ani and proctalgia fugax, and how to optimize treatment of each.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eBonus Session K: Laser-Focused on IBD Targets – Disease Monitoring Strategies\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eModerator: Edith Y. Ho, MD, MS, FACG\u003c\/em\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003ePin-Pointing Therapeutic Targets in Ulcerative Colitis\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eEdith Y. Ho, MD, MS, FACG\u003c\/em\u003e\u003cbr\u003eIncorporate updated recommendations for assessing UC disease activity.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eZooming in on Therapeutic Targets in Crohn’s Disease\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eBruce E. Sands, MD, MS, FACG\u003c\/em\u003e\u003cbr\u003eSummarize invasive and non-invasive strategies for achieving therapeutic goals in Crohn’s disease.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLocking in on Perianal Disease IBD Targets\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eDavid A. Schwartz, MD, FACG\u003c\/em\u003e\u003cbr\u003eFormulate treat-to-target strategies in managing perianal Crohn’s disease.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eBonus Session L: ACG’s New Guidelines on Clinical Use of Esophageal Physiologic Testing: How I Do It\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eModerator: C. Prakash Gyawali, MD, MRCP, FACG\u003c\/em\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eObstructive Symptoms: How Best to Sort Out Dysphagia and Regurgitation\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eC. Prakash Gyawali, MD, MRCP, FACG\u003c\/em\u003e\u003cbr\u003eExplain best approaches to obstructive symptoms with and without concurrent reflux symptoms.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTypical and Refractory Reflux Symptoms: Making the Most of Our Diagnostic Toolbox\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eAmit Patel, MD\u003c\/em\u003e\u003cbr\u003eCompare and contrast different approaches to the evaluation of reflux.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eExtra-Esophageal and Atypical Symptoms: How We Can Do Better\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eCharlene Prather, MD, MPH\u003c\/em\u003e\u003cbr\u003eDiscuss current limitations in diagnosing extra-esophageal reflux (cough, LPR), and how improved patient evaluation can lead to improved management.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eBonus Session M: Hot Topics in Barrett’s Esophagus\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eModerator: Christine Y. Hachem, MD, FACG\u003c\/em\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eWhat’s New in BE Screening and Surveillance\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003ePrateek Sharma, MD, FACG\u003c\/em\u003e\u003cbr\u003eReview pearls of screening and surveillance in Barrett’s esophagus.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eWhat’s New in BE Ablation\/Prevention\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eSachin B. Wani, MD\u003c\/em\u003e\u003cbr\u003eDiscuss new ablation protocols and data for prevention in Barrett’s esophagus.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eManaging Difficult and Refractory BE – A Case-Based Discussion\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eChristine Y. Hachem, MD, FACG\u003c\/em\u003e\u003cbr\u003eIdentify management strategies for difficult or refractory Barrett’s esophagus.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eBonus Session N: Practicing Medicine in the Digital Age\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eModerator: Amy S. Oxentenko, MD, FACG\u003c\/em\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eTelemedicine in GI – A Revolutionary Practice Platform in the Post-COVID-19 World\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eEric D. Shah, MD, MBA, FACG\u003c\/em\u003e\u003cbr\u003eOutline ways to incorporate telemedicine into your daily clinical practice in the post-COVID-19 world.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBuilding Your Brand: Using Social Media to Improve Your Practice\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eAmy S. Oxentenko, MD, FACG\u003c\/em\u003e\u003cbr\u003eRecognize how to maximize your social media experience while avoiding potential pitfalls.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIncorporate Emerging Technologies and AI Into Your Daily Practice\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eSeth A. Gross, MD, FACG\u003c\/em\u003e\u003cbr\u003eExplore the new frontiers of cutting-edge technology and the use of artificial intelligence in GI practice.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eBonus Session O: Hepatology Consults: Case-Based Explorations\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eModerator: Ayse Aytaman, MD, FACG\u003c\/em\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eEvolving Management of Portal Hypertension: Beyond Non-Selective Beta Blockers\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eGuadalupe Garcia-Tsao, MD, FACG\u003c\/em\u003e\u003cbr\u003eDiscuss emerging evidence to guide clinical decision-making in the management of cirrhotic portal hypertension, using statins, microbiome, DOACs, albumin, and TIPS.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNew Approaches to Diagnosis and Management of DILI\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eHaripriya Maddur, MD\u003c\/em\u003e\u003cbr\u003eReview evidence-based guidance on the evaluation and management of drug-induced liver injury including immune checkpoint inhibitor-associated hepatitis.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eEvidence-Based Approach to Liver Masses and the Role of LI-RADS\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eAyse Aytaman, MD, FACG\u003c\/em\u003e\u003cbr\u003eOutline current guideline recommendations in the evaluation, diagnosis, and management of patients with liver lesions, and describe the utilization of LI-RADS, a standardized radiologic classification system for liver lesions.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003cbr\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"meducours","offers":[{"title":"Default Title","offer_id":42954402824290,"sku":"MED-AMB02785","price":20.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/ACG-Meeting-Bonus-Sessions-2021.jpg?v=1779375539","url":"https:\/\/meducourse.com\/products\/acg-meeting-bonus-sessions-2021","provider":"Meducourse","version":"1.0","type":"link"}